Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2000
06/14/2000EP1007527A1 Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same
06/14/2000EP1007520A1 2-aminopyridines containing fused ring substituents as nos inhibitors
06/14/2000EP1007512A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
06/14/2000EP1007098A2 Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
06/14/2000EP1007095A2 Chimeric toxins for targeted therapy
06/14/2000EP1007087A1 INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION
06/14/2000EP1007084A1 Immunogenic lhrh compositions and methods relating thereto
06/14/2000EP1007082A1 Modified tumor necrosis factor
06/14/2000EP1007080A1 Sustained peptide-release formulation
06/14/2000EP1007072A1 Glial cell line-derived neurotrophic factor receptors
06/14/2000EP1007055A1 Methods for the administration of amifostine
06/14/2000EP1007044A1 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
06/14/2000EP1007042A1 Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
06/14/2000EP1007035A1 Polythiophene anti-tumor agents
06/14/2000EP1007029A1 Methods and compositions for treatment of ovarian cancer
06/14/2000EP1007026A1 Integrin antagonists
06/14/2000EP1007010A2 Pharmaceutical composition comprising an azasteroid
06/14/2000EP0845985B1 Non-steroidal sulfatase inhibitor compounds
06/14/2000EP0830145B1 Formulations comprising leflunomide
06/14/2000CN1256696A Monoclonal antibody which recognizes the oligosaccharide N-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
06/14/2000CN1256687A Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
06/14/2000CN1256632A Suppression of malignancy utilizing ribonucleotide reductase R1
06/14/2000CN1256315A New gene related to the development of human's nervous system and the protein encoded with it
06/14/2000CN1256310A Process for preparing fowl paralysis virus using continuous avian cell line
06/14/2000CN1256146A Cancer treating medicine
06/14/2000CN1256126A Composite medicine for optical dynamic treatment of tumor
06/14/2000CN1053376C Antineoplastic Chinese medicine prepn. and its preparing process
06/14/2000CN1053362C Baicaoshengshou oral liquid and its prep.
06/13/2000US6075136 Polynucleotide sequence coding a polypeptide with enzymatic activity; for treating or preventing cancer and reproductive defects; anticarciongenic agents
06/13/2000US6075135 3,4-di-O,N-Protected-4-amino-2,4,6-trideoxy-2-fluoro-L-manno-pyranosyl halide and a process for its preparation
06/13/2000US6075054 Antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment as well as for the treatment of angina pectoris
06/13/2000US6075033 Anthranilic acid diamides derivatives, their preparation and pharmaceutical use as anti-gastrin agents
06/13/2000US6075032 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
06/13/2000US6075008 Method for promoting cell proliferation and growth
06/13/2000US6075006 For treatment of arthritis, asthma, inflammation, tumoral growth, gastro intestinal hypermotility, huntington disease, neuritis, neuralgia, migraine, hypertension, incontinence of urine, urticaria, symptoms of the carcinoid syndrome
06/13/2000US6074873 Nucleic acids encoding NL-3
06/13/2000US6074848 Amino acid sequence; for antiproliferative and wound healing agents
06/13/2000US6074841 Don-1 gene and polypeptides and uses therefor
06/13/2000US6074839 Transforming growth factor αHI
06/13/2000US6074666 Liposome compositions of porphyrin photosensitizers
06/13/2000US6074650 Membrane anchor/active compound conjugate, its preparation and its uses
06/13/2000US6074648 Galenic preparation for prevention and treatment of hepatocarcinoma
06/13/2000US6074644 Cytotoxic activity
06/13/2000US6074643 Site-directed chemotherapy of metastases
06/13/2000US6074640 Preadministering antibody before radiation
06/13/2000US6074637 Modifying cells by transfection with dna
06/13/2000US6074626 Radioactive cisplatin in the treatment of cancer
06/13/2000CA2118309C Lymphocyte activation antigen hb15, a member of the immunoglobulin superfamily
06/13/2000CA2077537C Therapeutically useful peptides and peptide fragments
06/13/2000CA2000979C Specific ligands of receptors of oestrogen and progesterone steroidal hormones, use and synthetic intermediates
06/09/2000CA2289951A1 Processes for preparation of marek's disease virus using continuous avian cell lines
06/08/2000WO2000033069A1 Substance containing shiitake mushroom hypha extract for screening lak activity and method for screening lak activity by using the same
06/08/2000WO2000032818A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
06/08/2000WO2000032816A1 Antisense modulation of cellular inhibitor of apoptosis-1 expression
06/08/2000WO2000032778A2 Methods and compositions for inhibiting neoplastic cell growth
06/08/2000WO2000032776A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
06/08/2000WO2000032769A2 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
06/08/2000WO2000032767A1 RECOMBINANT SOLUBLE Fc RECEPTORS
06/08/2000WO2000032764A1 New oligomeric conjugates liable to transfer biological molecules into cells
06/08/2000WO2000032752A1 Psca: prostate stem cell antigen and uses thereof
06/08/2000WO2000032631A2 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof
06/08/2000WO2000032584A2 Nonsteroidal antiinflammatories
06/08/2000WO2000032583A1 Antitumor dibenzofluorene derivatives
06/08/2000WO2000032579A1 Substituted benzimidazoles and their use as parp inhibitors
06/08/2000WO2000032578A1 Benzimidazole compounds that are vitronectin receptor antagonists
06/08/2000WO2000032570A1 Hydrazine derivatives
06/08/2000WO2000032255A1 Polymeric coatings with controlled delivery of active agents
06/08/2000WO2000032237A1 Pharmaceutical composition comprising an anti-cancer agent and at least a peptide
06/08/2000WO2000032236A1 Peptides carrying substances across the blood brain barrier
06/08/2000WO2000032235A1 Transport system conjugate
06/08/2000WO2000032231A1 Stimulation of t cells against self antigens using ctla-4 blocking agents
06/08/2000WO2000032227A2 Ordered molecular presentation of antigens, method of preparation and use
06/08/2000WO2000032221A2 Promotion or inhibition of angiogenesis and cardiovascularization
06/08/2000WO2000032218A1 Controlled release formulation comprising gnrh-ii
06/08/2000WO2000032217A1 Small peptides and methods for treatment of asthma and inflammation
06/08/2000WO2000032216A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
06/08/2000WO2000032213A1 ηδT CELL IMMUNOACTIVITY POTENTIATORS CONTAINING SHIITAKE MUSHROOM HYPHA EXTRACT
06/08/2000WO2000032212A1 Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same
06/08/2000WO2000032189A1 Celecoxib compositions
06/08/2000WO2000032186A2 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
06/08/2000WO2000032175A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
06/08/2000WO2000016760A3 New use of prostaglandin e2 antagonists
06/08/2000WO2000015820A8 Adenovirus vectors containing cell status-specific response elements and methods of use thereof
06/08/2000WO2000015659A3 Stomach polypeptide zsig28
06/08/2000WO2000012541A3 Cytotoxic peptides modified by bulky or lipophilic moieties
06/08/2000WO2000009086A3 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
06/08/2000WO2000008191A3 Herpes virus vectors for dendritic cells
06/08/2000WO2000004137A9 Human aspartic proteases
06/08/2000DE19959689A1 Liposome composition for tumor, especially breast cancer, therapy comprises an alkyl phospholipid with antineoplastic activity and one or more antiestrogens
06/08/2000DE19958198A1 Mit dem IGF-1 Rezeptor wechselwirkende Proteine (IIPs) With the IGF-1 receptor interacting proteins (IIPs)
06/08/2000DE19856463A1 Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren Retroviral pseudotyped with LCMV hybrid vectors
06/08/2000DE19856052A1 Konjugat zur Anreicherung in neuronalen Zellen Conjugate to accumulate in neuronal cells
06/08/2000DE19855963A1 Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung Amphiphilic glyceryl, processes for their preparation and their use
06/08/2000DE19832840C1 Mittel zur Immuntherapie von Tumorerkrankungen Means for immunotherapy of tumors
06/08/2000CA2566516A1 Psca: prostate stem cell antigen and uses thereof
06/08/2000CA2354183A1 Ordered molecular presentation of antigens, method of preparation and use
06/08/2000CA2353798A1 Controlled release formulation comprising gnrh-ii
06/08/2000CA2353550A1 Small peptides and methods for treatment of asthma and inflammation
06/08/2000CA2353521A1 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof
06/08/2000CA2353108A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
1 ... 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 ... 2211